203 related articles for article (PubMed ID: 15945504)
1. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Dudek AZ; Mahaseth H
Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
[TBL] [Abstract][Full Text] [Related]
2. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
3. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.
Ueno K; Inoue Y; Kawaguchi T; Hosoe S; Kawahara M
Lung Cancer; 2001; 31(2-3):213-9. PubMed ID: 11165400
[TBL] [Abstract][Full Text] [Related]
5. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer.
Liu SG; Yuan SH; Wu HY; Liu J; Huang CS
Cell Biochem Biophys; 2015 May; 72(1):165-9. PubMed ID: 25548002
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations.
Hu M; Zhang T; Gu M; Li J; Zhang H; Wang Q; Hu F; Yang Y; Li B
Genet Test Mol Biomarkers; 2020 Dec; 24(12):798-803. PubMed ID: 33347392
[No Abstract] [Full Text] [Related]
8. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
10. Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.
Garpenstrand H; Bergqvist M; Brattström D; Larsson A; Oreland L; Hesselius P; Wagenius G
Med Oncol; 2004; 21(3):241-50. PubMed ID: 15456951
[TBL] [Abstract][Full Text] [Related]
11. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
Choi JH; Kim HC; Lim HY; Nam DK; Kim HS; Yi JW; Chun M; Oh YT; Kang S; Park KJ; Hwang SC; Lee YH; Hahn MH
Lung Cancer; 2001; 33(2-3):171-9. PubMed ID: 11551412
[TBL] [Abstract][Full Text] [Related]
13. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
[TBL] [Abstract][Full Text] [Related]
14. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
[TBL] [Abstract][Full Text] [Related]
15. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients.
Seker MM; Sancaktar E; Acibucu DO; Filiz AK; Deveci K; Bahceci A; Kacan T; Babacan N; Yuce S
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2929-32. PubMed ID: 24254563
[TBL] [Abstract][Full Text] [Related]
17. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer.
Brattström D; Bergqvist M; Hesselius P; Larsson A; Wagenius G; Brodin O
Lung Cancer; 2004 Jan; 43(1):55-62. PubMed ID: 14698537
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
[TBL] [Abstract][Full Text] [Related]
19. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM; Camps C; Sirera R
Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]